Table 2.
Major phase 3 trials involving chemotherapeutic agents in the advanced/metastatic gastric cancer setting
| Trials | No. of patients | Treatment arms | HR for death (P value) | Primary endpoint comparison (in months) |
|---|---|---|---|---|
| Advanced gastric cancer – first line | ||||
| Van Cutsem et al. 24 (V325 study group) | 445 | DCF versus CF | TTP: 1.47 (<0.001) OS: 1.29 (0.02) | TTP: 5.6 versus 3.7OS: 9.2 versus 8.6 |
| Cunningham et al. 25 | 1,002 | ECF versus ECX versus EOF versus EOX | 0.80 (0.02) | OS: 9.9 versus 9.9 versus 9.3 versus 11.2 |
| Koizumi et al. 27 (SPIRITS) | 305 | S‐1 + Cisplatin versus S‐1 | 0.77 (0.04) | OS: 13.0 versus 11.0 |
| Advanced gastric cancer – Second line | ||||
| Ford et al. 30 (COUGAR ‐ 02) | 168 | Docetaxel + ASC versus ASC | 0.67 (0.01) | OS: 5.2 versus 3.6 |
| Thuss‐Patience et al. 31 (AIO) | 40 | Irinotecan + BSC versus BSC | 0.48 (0.012) | OS: 4.0 versus 2.4 |
HR, Hazard ratio; OS, Overall survival; DCF, Docetaxel, Cisplatin and 5‐FU; CF, Cisplatin and 5‐FU; TTP, Time to progression; ECF, Epirubicin, Cisplatin and 5‐FU; ECX, Epirubicin, Cisplatin and Capecitabine; EOF, Epirubicin, Oxaliplatin and 5‐FU, EOX: Epirubicine, Oxaliplatin and Capecitabine; BSC, Best supportive care; ASC, Active symptom control.